Background. We previously demonstrated the noninferiority of switching to efavirenz (EFV) versus remaining on ritonavir-boosted lopinavir (LPV/r) for virologic control in children infected with human immunodeficiency virus (HIV) and exposed to nevirapine (NVP) for prevention of mother-to-child transmission. Here we assess outcomes up to 4 years post-randomization.
The World Health Organization (WHO) now recommends antiretroviral treatment (ART) for all children and adults infected with human immunodeficiency virus (HIV), regardless of clinical disease stage [1] . Pediatric ART access has expanded considerably in recent years, though only half of 1.8 million HIV-infected children worldwide were on treatment in 2015 [2] . Enhanced efforts towards earlier diagnosis may improve pediatric ART uptake [3] , increasing the number of young children initiating lifelong ART. Treatment options that address the spectrum of pediatric health and development are needed.
WHO recommends a ritonavir-boosted lopinavir (LPV/r)-based regimen for treatment initiation <3 years of age, and an efavirenz (EFV)-based regimen for initiation at ≥3 years [1] . LPV/r was initially recommended for young children exposed to nevirapine (NVP) for prevention of mother-to-child transmission (PMTCT) [4] due to a high probability of NVP resistance [5] . Now evidence of superior virologic control with LPV/r in children with and without NVP exposure supports this strategy regardless of PMTCT [6] . However, long-term LPV/r use in children raises several concerns, including poor palatability, interactions with tuberculosis treatment, and potential metabolic complications. For young children initiated on LPV/r, WHO now recommends consideration of switching to EFV at 3 years of age when viral load monitoring is available [1] .
suppressed on LPV/r were randomized to remain on LPV/r or switch to EFV. At 48 weeks of follow-up, we found no evidence of compromised virologic control in children who switched to EFV [7] . Additionally, we observed improved lipid profiles and higher CD4 percentages in children who switched. Evidence of long-term safety and efficacy of this strategy is needed to alleviate concerns around switching clinically stable children to a non-nucleoside reverse transcriptase inhibitor (NNRTI) after prior exposure to NVP. Here we present outcomes through 4 years post-randomization in this trial.
METHODS

Study Population
Between June 2010 and December 2013, 300 perinatally HIVinfected children participated in a randomized, open-label noninferiority trial of switching to EFV at Rahima Moosa Mother and Child Hospital in Johannesburg, South Africa (Clinicaltrials. gov NCT01146873) [7] . Eligibility requirements included: age ≥3 years, exposure to NVP for PMTCT, initiation of LPV/rbased therapy <3 years of age continued for ≥1 year, and plasma HIV RNA <50 copies/mL. Children were randomized to switch to EFV or remain on LPV/r and followed for 48 weeks.
Following trial completion, participants were invited into a prospective observational study at the same site. The enrollment period was February 2013 to May 2014 and follow-up is ongoing. Mothers or legal guardians provided written informed consent separately for the clinical trial and the observational study. Written assent was obtained in the observational study from children ≥7 years of age capable of understanding the assent form. Both studies were approved by Institutional Review Boards at Columbia University and the University of Witwatersrand. This analysis includes follow-up through December 2015.
Study Procedures
Clinical trial procedures have been described [7] . Briefly, children attended visits at 4, 8, 16, 24, 32, 40 , and 48 weeks following randomization. Weight and height were measured, a detailed clinical exam was done, and antiretroviral medications were prescribed and dispensed with dose adjustments according to growth. EFV was prescribed once-daily in capsules. LPV/r was prescribed twice-daily in syrup or tablets for children able to swallow tablets. Unused medication was returned at each visit for adherence reconciliation. Plasma HIV RNA levels (AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0, Roche) were measured at baseline, 4, 8, 16, 24 , and 48 weeks, and CD4 counts and percentages were measured at baseline, 24 and 48 weeks. A fasting lipid panel was done at baseline and 40 weeks.
Following the clinical trial period, observational study visits were every 6 months and included a clinical exam and weight and height measurements. The study site did not serve as the child's HIV treatment clinic, and antiretroviral medications were prescribed elsewhere. Data on regimens and switches were collected by caregiver report, review of patient records, and communication with the treatment clinic. At annual visits, plasma HIV RNA levels (ABBOTT RealTime), CD4 counts and percentages, and lipid panels were conducted by BARC South Africa, an independent clinical trials laboratory (part of a global network of laboratories) contracted for this study. These annual tests were scheduled to ensure HIV RNA and CD4 measurements were done at least every 6 months inclusive of those done in routine care. Routine HIV RNA (AmpliPrep/COBAS® TaqMan® HIV-1 Test v2.0 or Cobas 6800/8800, Roche) and CD4 measurements were conducted by National Health Laboratory Service (NHLS); results were obtained from records.
Routine care visits were generally scheduled every 3 months. For children receiving care at Rahima Moosa, study visits were scheduled on the same day as routine visits when feasible.
Statistical Analysis
As the noninferiority trial is complete and reported, for this analysis incorporating the subsequent observational study period we followed conventional superiority analyses for ease of interpretation. Primary analyses were intention-to-treat, that is, comparing children as randomized in the original trial. Perprotocol analyses, censoring all visits after children switched treatment regimen away from their randomized assignment, were also done. We assessed factors associated with nonenrollment in the observational study using multivariable logistic regression. The cumulative probability of switching treatment regimens from the randomized assignment was estimated with the Kaplan-Meier method.
The primary outcome was elevated plasma HIV RNA, which we evaluated with two approaches. First, the frequency of HIV RNA 51-1000 copies/mL (viral rebound) and >1000 copies/ mL over time in each group was compared using generalized estimating equations (GEE). Second, time to virologic failure (HIV RNA >1000 copies/mL confirmed) was compared with Kaplan-Meier and the log-rank test. All HIV RNA tests regardless of the laboratory where they were run were included in the analyses. During the clinical trial, any HIV RNA >1000 copies/ mL prompted recall of the child for repeat testing. During the observational study, the schedule of repeat testing was at the discretion of the treating physician. We retained the definition of virologic failure as two HIV RNA tests >1000 copies/mL regardless of the time between samples and did not require consecutive results. This maintained consistency with the definition during the clinical trial and minimized potential misclassification when defining failure on the basis of an isolated measurement. Plasma samples from children with virologic failure were tested for drug resistance at the National Institute for Communicable Diseases [8] . HIV RNA database entries "below detectable limits" were assumed to be <50 copies/mL. Among these, ~10% of records were reviewed and of these >90% indicated the lower limit was <20 or <40 copies/mL. CD4 counts and percentages, abnormal and elevated lipids [9] , and growth parameters were compared over time with GEE. Growth parameters included WHO weight-for-age, heightfor-age, and body mass index (weight [kg]/height [meters] squared)-for-age Z-scores [10] . Assessments of lipids and growth were limited to those measured at study visits. Analyses were conducted in SAS 9.4 (SAS Institute, Cary NC).
RESULTS
Study Population and Follow-up
Of 300 children enrolled in the clinical trial, 148 were randomized to continue LPV/r, 150 were randomized to switch to EFV, and 2 discontinued prior to randomization. As previously reported, baseline sociodemographic and clinical characteristics were comparable across groups [7] . Median age at randomization was 4.1 years (interquartile range [IQR] 3.5-4.8), and 47% were male. Children initiated ART at a median age of 6.8 months (IQR 4.0-13.2) and 7% had a CD4 percentage <25.
Among children randomized to remain on LPV/r, 119 (80%) enrolled into long-term follow-up, and 118 (78%) in the EFV group enrolled. In multivariable analysis, the primary factor associated with nonenrollment was a longer time between the last trial visit and observational study start Table 1 ). Among children enrolled into long-term follow-up, characteristics at the time of randomization remained comparable across groups ( Table 1 ). The median time between the last clinical trial visit and enrollment into the observational study was 7 months, and the median follow-up time from randomization through December 2015 was 46 months. By the end of 2015, among the 298 children randomized in the clinical trial, 116 (78%) in the LPV/r group and 109 (73%) in the EFV group were retained. Follow-up detail is shown in Figure 1 .
In the EFV group, 4 children switched back to LPV/r by 1 year (probability 0.03, 95% CI 0.01-0.07) and 3 switched back during the second year (probability 0.05, 95% 0.03-0.11); no further switching was observed. Of these 7, 2 experienced seizures, 2 had virologic failure, and the reason for switching was unknown for 3 ( Figure 2 ).
In the LPV/r group, none switched to EFV during the trial. Thereafter, the cumulative number (and probability . Reasons for switching were lipid toxicity (n = 7), regimen simplification (n = 6), intolerable taste (n = 3), supply issues (n = 2), and 5 were unknown.
Virologic Outcomes
The odds of viral rebound (51-1000 copies/mL) through 48 months were lower in children randomized to EFV than in children randomized to remain on LPV/r (OR 0.67, 95% CI 0.51-0.88, P = .004) as were the odds of any HIV RNA >1000 copies/mL (OR 0.52, 95% CI 0.28-0.98, P = .04) (Figure 3a) . By 48 months, virologic failure (>1000 copies/mL confirmed) was observed in 14 children randomized to LPV/r (probability 0.12, 95% CI 0.08-0.20) and 8 randomized to EFV (probability 0.07, 95% CI 0.04-0.14, P = .21) (Figure 3b ). Per-protocol results were comparable. Resistance test results for children with virologic failure are displayed in Table 2 . No children had mutations conferring resistance to protease inhibitors. Four who failed in the EFV group had detectable nucleoside reverse transcriptase inhibitor (NRTI) resistance (primarily M184V/I) and NNRTI resistance (primarily K103N): 2 switched back to LPV/r and resuppressed, 1 switched to lamivudine monotherapy and transferred out, and 1 failed to resuppress in follow-up. Two children randomized to EFV who failed and did not have resistance testing resuppressed on EFV.
Among children randomized to remain on LPV/r with virologic failure, 3 had NRTI resistance (M184V, M41L) and resuppressed. Two had switched to EFV prior to failure, both had detectable NRTI (M184V) and NNRTI (K103N) resistance: 1 switched due to supply issues and viral loads remained high over 1 year, then switched back to LPV/r at the last observed visit; the other switched to EFV for unknown reasons and viral loads remained between 162 and 742 copies/mL. Among the 4 without resistance testing, three resuppressed and subsequent viral loads for 1 are unknown. 
Secondary Outcomes
Across all visits, CD4 percentages were 2.1 points higher on average in the EFV group compared to the LPV/r group (95% CI 0.7-3.5, P = .003) (Supplementary Figure 1) . CD4 counts did not differ by group, nor did the proportion with any immunosuppression (CD4 percentage <25 if <5 years of age or CD4 count <500 if ≥5 years [11] ).
We observed a reduced risk of elevated total cholesterol in the EFV group compared to the LPV/r group (OR 0.45, 95% CI: 0.27-0.75, P = .002), as well as a reduced risk of abnormal triglycerides (OR 0.42, 95% CI 0.29-0.62, P < .001) and a reduced risk of elevated low-density lipoprotein (OR 0.45, 95% CI 0.24-0.84, P = .01) (Figure 4) . Abnormal high-density lipoprotein was less frequently observed in the EFV group, though not statistically significant (OR 0.55, 95% CI 0.25-1.20, P = .13). Weight-for-age, height-for-age, and body mass index-for-age Z-scores did not differ across groups. Per-protocol results of secondary outcomes were comparable.
Adherence based on medication reconciliation did not differ by group during the clinical trial though medicine containers were left at home more frequently in the LPV/r group [7] . During the observational study, caregivers reported that the child "ever" missed a dose since the last visit at 8% of visits in the EFV group and at 13% of visits in the LPV/r group (OR 0.63, 95% CI 0.40-0.97, P = .04).
DISCUSSION
Among HIV-infected children exposed to NVP for PMTCT and virally suppressed on LPV/r, we observed comparable virologic control (<1000 copies/mL) in children randomized to switch to EFV versus those randomized to remain on LPV/r through 4 years of follow-up. Importantly, children who switched to EFV experienced viral rebound (51-1000 copies/ mL) less frequently than children who remained on LPV/r and had improved lipid profiles and somewhat higher CD4 percentages. Our results demonstrate that the benefits of switching to EFV reported through 48 weeks in the clinical trial [7] were sustained through 4 years. We observed clear benefits for reductions in lipid abnormalities. In this same study population, we have also reported improved bone mineral content in children who switched to EFV compared to those who remained on LPV/r [12] . Some trials have observed lower weight in children initiating LPV/r compared to NNRTI-based regimens [6, [13] [14] [15] . We did not observe this difference, similar to a trial from Figure 3 . Elevated plasma HIV RNA by randomized assignment over time, represented by A, the frequency of HIV RNA 51-1000 and >1000 copies/mL at 6-monthly intervals, and B, the cumulative probability of virologic failure (HIV RNA >1000 copies/mL confirmed) up to 48 months. Abbreviation: EFV, efavirenz; LPV/r, ritonavir-boosted lopinavir; VL, viral load. Figure 2 . Cumulative probability of switching treatment regimen away from randomized assignment through 48 months. The solid gray line shows the probability of switching to EFV among children randomized to LPV/r; the dashed black line shows the probability of switching to LPV/r among children randomized to EFV. Abbreviations: EFV, efavirenz; LPV/r, ritonavir-boosted lopinavir. Uganda [16] . Notably, differences observed have been small [14] and may diminish over time [15] . In long-term follow-up, we found superior caretaker-reported adherence in children switched to EFV. In the clinical trial, medicine reconciliation, a more robust measure of adherence, did not differ by group, though containers were not returned more frequently in the LPV/r group [7] . Despite limitations of self-reported adherence, these observations are consistent with the poor taste of LPV/r and more frequent viremia seen in the LPV/r group. Sustained adherence in young children is a formidable challenge and even small improvements gained with a regimen change could lead to better outcomes over the long term. Notably, in both groups, few children experienced virologic failure. This cohort of young children remained highly adherent after transitioning from close clinical trial monitoring to standard clinical care, indicating that families can maintain the long-term commitment to supporting adherence in children. Simplified regimens can further support adherence [17, 18] ; we hypothesize that once-daily EFV provided an adherence advantage over twice-daily LPV/r in our study.
We were surprised by the relatively low uptake of the switch strategy in the cohort after the trial ended. WHO guidelines currently recommend consideration of switching to EFV at age ≥3 years in clinically stable children [1] , however South African guidelines do not yet recommend switching [19] . The limited uptake may reflect the relative recency of the publication of our trial results or concerns about the long-term viral efficacy of the strategy. These results through 4 years of follow-up, together with increasingly available viral load monitoring, may offer reassurance to clinicians considering a regimen switch.
In terms of limitations of EFV, 2 children developed seizures in our study, underscoring the importance of close clinical monitoring. Both had high plasma EFV concentrations, and polymorphisms in cytochrome P450 (CYP) 2B6 associated with reduced metabolism of EFV [20] . EFV dosing was consistent with South African guidelines [21] . Another potential concern with EFV is the lower genetic barrier to resistance compared to LPV/r [22] . We are reassured that virologic failures were uncommon and comparable across the groups 4 years after randomization. Also, we found that children with adequate adherence who restarted on LPV/r promptly after failure on EFV were not compromised by their experience with EFV. Further, in the context of routine viral load monitoring, we did not observe any developed resistance that would compromise newer NNRTI drugs [23] .
An important limitation of our study is that we do not have data on children with extended regimens of NVP. Nevertheless, we believe that the biological plausibility of longer regimens substantially attenuating our results is low. Almost all infants exposed to single dose [24, 25] or extended [26] NVP have measurable levels of NNRTI resistance when measured close to the exposure with suitable assays. However, these mutations decline over time, albeit more slowly in infants with extended NVP exposure [26, 27] . Interestingly, the most common specific mutation selected post-PMTCT is Y181C [24] , which confers about 2-fold reduced susceptibility to EFV compared to >40-fold reduced susceptibility to NVP [23, 28] .
A similar trial in western Africa provides some evidence that the benefits of switching to EFV extend to the current PMTCT era. In this trial, 106 HIV-infected children suppressed on LPV/r were randomized to switch to EFV or remain on LPV/r at a median age of 27 months [29] . A substantial proportion received extended NVP during breastfeeding. Overall suppression (HIV RNA <500 copies/mL) 12 months post-randomization was similar in the LPV/r (85.2%) and EFV (82.7%) groups. Inference is limited by the small sample size.
A strength of our analysis is preservation of the randomized design while assessing the durability of effects when children were referred out into routine care. Our results provide reassurance about the generalizability of benefits of the EFV switch strategy to a real-world setting. Unfortunately, only 80% of the original trial participants enrolled in the observational study largely due to the gap between trial completion and observational study start. Nevertheless, once enrolled, retention has been excellent with 95% still in follow-up. Among those retained, 95% had the opportunity be followed up for 3 years by the end of 2015, and 54% were followed up to 4 years. Results were consistent at 3 and 4 years. We intend to continue to follow up the cohort for longer term outcomes.
New regimens are on the horizon in Sub-Saharan Africa. Integrase inhibitors, including dolutegravir, have few side effects, a higher barrier to resistance, and excellent virologic control in adults; data in children are promising [30] . We are hopeful that dolutegravir will be available in pediatric formulations in resource-limited settings soon. Although awaiting regimens in the pipeline, consideration of switching to EFV at 3 years of age remains an important strategy to minimize the risk of metabolic complications and maximize bone health.
In conclusion, our results support the strategy of switching clinically stable HIV-infected children 3 years of age and older from LPV/r to EFV. In 4 years of follow-up, we observed less frequent viral rebound, improved lipid profiles, and higher CD4 percentages in children who switched to EFV compared to those who remained on LPV/r.
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